Transdermal system approved for overactive bladder
Watson Pharma, Inc., has received FDA approval to market oxybutynin transdermal system (Oxytrol) for the treatment of overactive bladder, with symptoms of urge urinary incontinence, urgency, and frequency. A thin patch applied to the abdomen, hip, or buttock twice weekly, it delivers 3.9 mg per day of oxybutynin consistently and continuously through the skin into the bloodstream, according to the company.
Jessica Feehan, NP-C, discusses the expanding role of APPs in urology, from clinical leadership and procedures to care coordination and treatment initiation.
Sam S. Chang, MD, MBA, discusses treatment selection after BCG failure, including bladder-sparing options, cystectomy considerations, and the need for sequencing data.
Justin B. Ziemba, MD, discusses clinical factors that help identify patients at increased risk for kidney stone recurrence and guide metabolic evaluation.
Adam Sharp, PhD, BM, MRCP, BSc, discusses preliminary safety and efficacy findings from a phase 1/2 study of gedatolisib plus darolutamide in patients with mCRPC.